What does “VivoScipt” mean?

What does Vivoscript do?

What is IVR?

What intellectual properties do you have?

What applications can IVR have?

What are the potential advantages of IVR therapeutics over conventional drug-based therapeutics and cell-based therapeutics?

Who do we work with?

What is our business model?

What does “VivoScipt” mean?

“VivoScript” means the script of life. A zygote develops into an individu al consisting of a complex system of tissues and cell types over years. This well-controlled differentiation process from the zygote to multipotent stem cells and various types of cells is all hardwired in the script, an extensive Gene Regulatory Network (GRN), directed by the genome of the cell. It was previously believed that this process is not reversible, and the majority of somatic cells were terminally differentiated and lacked the capability of changing to other types of somatic cells. This paradigm has now been toppled by Dr. Yamanaka and other scientists. The script is not fixed, and cell fates can be controlled. Our technology platform is established based on this principle.

What does Vivoscript do?

Our company focuses on rewriting the script of life (GRN) without changing the cell genome, curing human diseases by changing cell fates. For example, in one project, we convert hepatocytes to pancreatic B cells to treat diabetes, by changing the state of GRN of hepatocytes using a combination of protein drugs.


What is IVR?

To find a cure for the incurable diseases, we are developing a new technology platform, called In Vivo Cell Reprogramming, or IVR. The goal of the IVR approach is to achieve the 4R’s—cell regeneration, replacement, repair, and rejuvenation; the holy grail of regenerative medicine. Using a combination of protein drugs (and/or small molecule drugs), we can convert one type of cells to another type of cells. Borrowing terms from enzymology, we named the starting cells we wish to reprogram “substrate cells” and the reprogrammed cells ready for use “product cells.”

What intellectual properties do you have?

We have multiple patent applications covering the platform technology and its applications in several diseases. We also have technical know-how covering systematic approaches in selecting reprogramming factors, and designing and producing these proteins.

What applications can IVR have?

;

IVR can be used for many incurable and devastating diseases. Some examples are given in the following table.

Disease

Substrate Cell

Product Cell

Diabetes

liver cells

pancreatic exocrine cells

beta cells

 

Autoimmune diseases

T cells

Regulatory T cells

Obesity

White fat cells

Brown fat cells

Stroke

Astrocytes

Neurons

Myocardial infarction

Cardiac fibroblasts

Cardiomyocytes

What are the potential advantages of IVR therapeutics over conventional drug-based therapeutics and cell-based therapeutics?

Although great advances have been made in biomedical research, scientists and clinicians are still looking for effective treatments for some of the most devastating diseases, such as diabetes, cardiovascular diseases, spinal cord injury, Parkinson’s disease, and Alzheimer’s disease. Potential treatments for these diseases include drug-based, and cell-based therapies, however both of approaches have their limitations. Drug-based therapies usually treat the symptoms of a disease only and make patients chronically dependent on them. Cell-based therapies are hampered by the scarcity of the source, immune rejection, high costs in manufacture and distribution, and high risks in development and commercialization.

IVR combines the advantages of drug-based and cell-based therapies while avoiding the shortfalls of both. Since the modality of IVR therapeutics are proteins, their risk profiles and cost structures of development and commercialization are similar to those of drug-based therapies. However, by using a cell-based mechanism, IVR based treatments can achieve therapeutic benefits that cannot be achieved by conventional drugs. Additionally, the newly created product cells are self-sustainable, allowing short courses of treatment to provide long-term clinical benefits. Furthermore, contrary to most situations in cell or tissue transplantation, new product cells will not cause immune rejection since the substrate cell originates from the patient.

Who do we work with?

We have applied IVR to several disease areas, including diabetes, autoimmune diseases, and stroke. We are currently collaborating with several academic institutes and have generated some exciting data. We are also looking for partners to license part of whole of the IVR technology platform.

What is our business model?

Licensing is the main business model. We also market and sell the protein drug candidates in various projects as research reagents.